MEDPLUSMedplus Health Services Ltd.

    Medplus Health Services plans ₹130 crore share buyback at up to ₹750

    • Capital raise
    • Healthcare and pharmacy retail

    Medplus Health Services (NSE: MEDPLUS) has approved a share buyback of up to ₹130 crore through the open market, at a maximum price of ₹750 a share, it said in a filing on 10 Nov 2026. The Board approved the buyback on 06 Nov 2026 for fully paid-up equity shares of face value ₹2 each, held by shareholders other than promoters.

    Key highlights

    • Maximum buyback size: ₹130 crore excluding transaction costs
    • Maximum price: ₹750 per equity share, payable in cash
    • Indicative maximum shares: 17,33,333, or 1.44% of paid-up capital
    • Offer opens: 13 Nov 2026

    The buyback in numbers

    ItemDetail
    RouteOpen market, through the stock exchange mechanism
    Maximum size₹130 crore, excluding transaction costs
    Maximum price₹750 per equity share, in cash
    Indicative maximum shares17,33,333 (1.44% of paid-up equity capital)
    Minimum size₹97.50 crore, or 75% of the maximum
    Amount in first halfAt least ₹52 crore, or 40% of the maximum, within the initial half of the buyback period
    Opening date13 Nov 2026
    Escrow₹32.50 crore, or 25% of the maximum, with ICICI Bank Limited as escrow bank

    Size, price and share count

    The Board approved the buyback on 06 Nov 2026 with a maximum size of ₹130 crore and a maximum price of ₹750 a share. At the maximum price and size, the indicative number of shares is 17,33,333.

    The company puts the maximum size at 9.87% of paid-up equity capital and free reserves on its audited standalone accounts and 6.61% on its consolidated accounts, both as at 31 Mar 2026. It says this is within the 10% limit, so shareholder approval is not required. The company says the buyback is meant to optimise returns to shareholders and enhance shareholder value.

    Against Blacklitt's market value of ₹7,160 crore at the 09 Nov 2026 close, the maximum size is about 1.8%. It is also about 2.3 times the consolidated net profit of ₹56.07 crore reported for Q2 FY27.

    Funding and escrow

    The company says the buyback will be funded from its securities premium account, free reserves, cash and cash equivalents and internal accruals, and not from borrowed funds.

    The company will deposit ₹32.50 crore, or 25% of the maximum size, in an escrow account with ICICI Bank Limited as escrow bank. The buyback is implemented through the stock exchanges by order matching, and shareholders holding physical shares must dematerialise them to take part.

    Promoters, intermediaries and recent filings

    Promoters and the promoter group, who hold 40.19% of paid-up equity capital before the buyback, are not entitled to participate and will not sell shares in it. Nuvama Wealth Management Limited is the manager, merchant banker and broker to the buyback, and KFin Technologies Ltd is the registrar. Shrenik Soni, Company Secretary and Compliance Officer, is the compliance officer. BSR and Co LLP issued a report on the buyback computation dated 06 Nov 2026.

    In the last 30 days the company's filings also include promoter encumbrance disclosures and takeover-code share disclosures, dated 28 Oct, 30 Oct and 31 Oct 2026.

    What the buyback means for Medplus Health Services shareholders

    The company will buy back shares from shareholders other than promoters, in the open market, up to a maximum of ₹130 crore at no more than ₹750 a share. The amount actually spent and the number of shares actually bought depend on market prices during the offer.

    Not stated in the filing: the actual number of shares bought or price paid, when the escrow deposit is made, and why the company chose a buyback over dividends or other uses of surplus funds. The next dated step is the opening of the offer on 13 Nov 2026.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Medplus Health Services Ltd. articles